<?xml version="1.0" encoding="UTF-8"?>
<p>In summary, Zhang 
 <italic>et al</italic> demonstrates that antiviral therapy and careful viral monitoring allows safe administration of CPIs to HBV infected cancer patients and demonstrates a management approach that is readily adoptable both in Asia and in the West.
 <xref rid="R7" ref-type="bibr">7</xref> Additionally, Ramsey 
 <italic>et al</italic> demonstrate that screening for high risk patients as defined in the recent ASCO clinical opinion report
 <xref rid="R5" ref-type="bibr">5</xref> is potentially a cost effective approach in the West, yielding new viral carrier diagnoses in asymptomatic cancer patients.
 <xref rid="R10" ref-type="bibr">10</xref> This is particularly relevant given the increasing utilization of CPIs in patients with a broad range of cancer diagnoses.
</p>
